Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068999 | 1.00 | CTSK (0.40) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL31001833 | 1.00 | CTSK (0.40) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL31001802 | 1.00 | CTSK (0.40) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL25124204 | 0.87 | HSD17B10 (0.43) | CTSKCHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL5431465 | 0.85 | CTSK (0.39) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL25866969 | 0.85 | CTSK (0.39) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL5431463 | 0.85 | CTSK (0.39) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL9383049 | 0.85 | CTSK (0.39) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL22644358 | 0.85 | CTSK (0.39) | CTSKDPP4CHRM2CHRM1CHRM3 | |
| SCHEMBL3442971 | 0.82 | CTSK (0.40) | CTSKDPP4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025026903-A1 | IMIDAZO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-06 | — | — | WO | disclosed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| EP-1729772-B1 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1729772-B1 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2016-12-07 | — | — | EP | disclosed |
| CN-101821257-B | 5-HT7 receptor antagonists | LILLY CO ELI | 2013-05-22 | — | — | CN | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-7825135-B2 | Heteroaryl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| CN-101821257-A | 5-HT 7Receptor antagonist | LILLY CO ELI | 2010-09-01 | — | — | CN | disclosed |
| EP-1729772-A4 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
| EP-1729772-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck and Co., Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094514-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005094514-A2 | HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254880-A1 | Heteroaryl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | CTSK 3866/4885DPP4 643/4885CHRM2 3096/4885 |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | WNT1, CTNNB1, WNT3 | CTSK 3151/4885DPP4 1550/4885CHRM2 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.